Characterization of Clostridium difficile Strains in British Columbia, Canada: A Shift from NAP1 Majority (2008) to Novel Strain Types (2013) in One Region

Canadian Journal of Infectious Diseases and Medical Microbiology

Volumn 2016, Issue , 2016, Pages

  Jassem, Agatha N ^a,b   Prystajecky, Natalie ^a,b   Marra, Fawziah ^a,b   Kibsey, Pamela ^c   Tan, Kennard ^c   Umlandt, Patricia ^a   Janz, Loretta ^a   Champagne, Sylvie ^d   Gamage, Bruce ^e   Golding, George R ^f   Mulvey, Michael R ^f   Henry, Bonnie ^a,b   Hoang, Linda M N ^a,b  

^a BRITISH COLUMBIA CENTRE FOR DISEASE CONTROL   (Canada)

^b UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^c Island Health   (Canada)

^d Providence Health Care   (Canada)

^e Provincial Infection Control Network of British Columbia   (Canada)

^f PUBLIC HEALTH AGENCY OF CANADA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

CLINDAMYCIN; METRONIDAZOLE; NUCLEOSOME ASSEMBLY PROTEIN 1; VANCOMYCIN;

ADOLESCENT; ADULT; AGED; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIAL STRAIN; BACTERIUM ISOLATE; BRITISH COLUMBIA; CHILD; CLOSTRIDIUM DIFFICILE INFECTION; COMMUNITY ACQUIRED INFECTION; CONTROLLED STUDY; FOLLOW UP; GENOTYPE; HOSPITAL INFECTION; HUMAN; INFANT; MAJOR CLINICAL STUDY; MINIMUM INHIBITORY CONCENTRATION; MOLECULAR EPIDEMIOLOGY; NEWBORN; NONHUMAN; PEPTOCLOSTRIDIUM DIFFICILE; POLYMERASE CHAIN REACTION; PULSED FIELD GEL ELECTROPHORESIS; RIBOTYPING;

EID: 84971475743     PISSN: 17129532     EISSN: 19181493     Source Type: Journal    
DOI: 10.1155/2016/8207418     Document Type: Article

References (53)

1. CDC, "Antibiotic resistance threats in the United States, 2013, " Centers for Disease Control and Prevention Report, 2013.
2. M. J. Garner, C. Carson, E. J. Lingohr, A. Fazil, V. L. Edge, and J. Waddell, "An assessment of antimicrobial resistant disease threats in Canada, " PLoS ONE, vol. 10, no. 4, Article ID0125155, 2015.
3. J. J. Hunt and J. D. Ballard, "Variations in virulence and molecular biology among emerging strains of Clostridium difficile, " Microbiology and Molecular Biology Reviews, vol. 77, no. 4, pp. 567-581, 2013.
4. J. M. Keller and C. M. Surawicz, "Clostridium difficile infection in the elderly, " Clinics in Geriatric Medicine, vol. 30, no. 1, pp. 79-93, 2014.
5. S. Y. Tartof, K. C. Yu, R. Wei, H. F. Tseng, S. J. Jacobsen, and G. K. Rieg, "Incidence of polymerase chain reaction-diagnosed clostridiumdifficile in a large high-risk cohort, 2011-2012, " Mayo Clinic Proceedings, vol. 89, no. 9, pp. 1229-1238, 2014.
6. M. He, F. Miyajima, P. Roberts et al., "Emergence and global spread of epidemic healthcare-associated Clostridium difficile, " Nature Genetics, vol. 45, no. 1, pp. 109-113, 2013.
7. B. Dupuy, R. Govind, A. Antunes, and S. Matamouros, "Clostridium difficile toxin synthesis is negatively regulated by TcdC, " Journal of Medical Microbiology, vol. 57, no. 6, pp. 685-689, 2008.
8. S. T. Cartman, M. L. Kelly, D. Heeg, J. T. Heap, and N. P. Minton, "Precise manipulation of the Clostridium difficile chromosome reveals a lack of association between the tcdC genotype and toxin production, " Applied and Environmental Microbiology, vol. 78, no. 13, pp. 4683-4690, 2012.
9. R. Murray, D. Boyd, P. N. Levett, M. R. Mulvey, and M. J. Alfa, "Truncation in the tcdC region of the Clostridium difficile PathLoc of clinical isolates does not predict increased biological activity of Toxin B or Toxin A, " BMC Infectious Diseases, vol. 9, article 103, 2009.
10. M. Merrigan, A. Venugopal, M. Mallozzi et al., "Human hypervirulent Clostridium difficile strains exhibit increased sporulation as well as robust toxin production, " Journal of Bacteriology, vol. 192, no. 19, pp. 4904-4911, 2010.
11. D. Bakker, W. K. Smits, E. J. Kuijper, and J. Corver, "TcdC does not significantly repress toxin expression in Clostridiumdifficile 630?Erm, " PLoS ONE, vol. 7, no. 8, Article ID e43247, 2012.
12. L. C. McDonald, G. E. Killgore, A. Thompson et al., "An epidemic, toxin gene-variant strain of Clostridium difficile, " The NewEngland Journal ofMedicine, vol. 353, no. 23, pp. 2433-2441, 2005.
13. M. Warny, J. Pepin, A. Fang et al., "Toxin production by an emerging strain of Clostridium difficile associated with outbreaks of severe disease in North America and Europe, " The Lancet, vol. 366, no. 9491, pp. 1079-1084, 2005.
14. C. Schwan, B. Stecher, T. Tzivelekidis et al., "Clostridiumdifficile toxin CDT induces formation of microtubule-based protrusions and increases adherence of bacteria, " PLoS Pathogens, vol. 5, no. 10, Article ID e1000626, 2009.
15. C. Gonçalves, D. Decré, F. Barbut, B. Burghoffer, and J.-C. Petit, "Prevalence and characterization of a binary toxin (actinspecific ADP-ribosyltransferase) from Clostridium difficile, " Journal of Clinical Microbiology, vol. 42, no. 5, pp. 1933-1939, 2004.
16. B. Geric, S. Johnson, D. N. Gerding, M. Grabnar, and M. Rupnik, "Frequency of binary toxin genes among Clostridium difficile strains that do not produce large clostridial toxins, " Journal of Clinical Microbiology, vol. 41, no. 11, pp. 5227-5232, 2003.
17. D. Lachowicz, H. Pituch, and P. Obuch-Woszczatýnski, "Antimicrobial susceptibility patterns of Clostridium difficile strains belonging to different polymerase chain reaction ribotypes isolated in Poland in 2012, " Anaerobe, vol. 31, pp. 37-41, 2015.
18. M. Miller, D. Gravel, M. Mulvey et al., "Health care-associated Clostridium difficile infection in Canada: patient age and infecting strain type are highly predictive of severe outcome and mortality, " Clinical Infectious Diseases, vol. 50, no. 2, pp. 194-201, 2010.
19. A.-C. Labbé, L. Poirier, D. MacCannell et al., "Clostridium difficile infections in a Canadian tertiary care hospital before and during a regional epidemic associated with the BI/NAP1/027 strain, " Antimicrobial Agents and Chemotherapy, vol. 52, no. 9, pp. 3180-3187, 2008.
20. S. B. Debast, M. P. Bauer, I. M. J. G. Sanders, M. H. Wilcox, and E. J. Kuijper, "Antimicrobial activity of LFF571 and three treatment agents against Clostridium difficile isolates collected for a pan-European survey in 2008: clinical and therapeutic implications, " Journal of Antimicrobial Chemotherapy, vol. 68, no. 6, pp. 1305-1311, 2013.
21. J. S. Brazier, R. Raybould, B. Patel et al., "Distribution and antimicrobial susceptibility patterns of Clostridiumdifficile PCR ribotypes in English hospitals, 2007-08, " Euro Surveillance, vol. 13, no. 41, article 3, 2008.
22. M. P. Hensgens, A. Goorhuis, D. W. Notermans, B. H. van Benthem, and E. J. Kuijper, "Decrease of hypervirulent Clostridium difficile PCR ribotype 027 in the Netherlands, " Euro Surveillance, vol. 14, no. 45, 2009.
23. M. P. Bauer, D. W. Notermans, B. H. B. van Benthem et al., "Clostridium difficile infection in Europe: A hospital-based survey, " The Lancet, vol. 377, no. 9759, pp. 63-73, 2011.
24. M. H. Wilcox, N. Shetty, W. N. Fawley et al., "Changing epidemiology of Clostridium difficile infection following the introduction of a national ribotyping-based surveillance scheme in England, " Clinical Infectious Diseases, vol. 55, no. 8, pp. 1056-1063, 2012.
25. J. Freeman, M. P. Bauer, S. D. Baines et al., "The changing epidemiology of Clostridiumdifficile infections, " ClinicalMicrobiology Reviews, vol. 23, no. 3, pp. 529-549, 2010.
26. F. C. Lessa, C. V. Gould, and L. C. McDonald, "Current status of Clostridium difficile infection epidemiology, " Clinical Infectious Diseases, vol. 55, supplement 2, pp. S65-S70, 2012.
27. PICNet, Clostridium difficile Infection (CDI) Surveillance Report: For the Fiscal Year 2013/2014, Provincial Infection Control Network of British Columbia, 2014.
28. T. Delate, G. Albrecht, K. Won, and A. Jackson, "Ambulatorytreated Clostridium difficile infection: A comparison of community-acquired vs. nosocomial infection, " Epidemiology and Infection, vol. 143, no. 6, pp. 1225-1235, 2015.
29. S. K. Taori, A. Wroe, A. Hardie, A. P. Gibb, and I. R. Poxton, "A prospective study of community-associated Clostridiumdifficile infections: The role of antibiotics and co-infections, " Journal of Infection, vol. 69, no. 2, pp. 134-144, 2014.
30. B.-M. Shin, S. J. Moon, Y. S. Kim, W. C. Shin, and H. M. Yoo, "Characterization of cases of Clostridium difficile infection (CDI) presenting at an emergency room:Molecular and clinical features differentiate community-onset hospital-associated and community-associated CDI in a tertiary care hospital, " Journal of Clinical Microbiology, vol. 49, no. 6, pp. 2161-2165, 2011.
31. S. Naggie, J. Frederick, B. C. Pien et al., "Community-associated Clostridium difficile infection: experience of a veteran affairs medical center in southeastern USA, " Infection, vol. 38, no. 4, pp. 297-300, 2010.
32. CDC, "Severe Clostridium difficile-associated disease in populations previously at low risk-four states, 2005, " Morbidity and MortalityWeekly Report, vol. 54, pp. 1201-1205, 2005.
33. M. J. Alfa, A. Kabani, D. Lyerly et al., "Characterization of a toxin A-negative, toxin B-positive strain of Clostridium difficile responsible for a nosocomial outbreak of Clostridium difficileassociated diarrhea, " Journal of ClinicalMicrobiology, vol. 38, no. 7, pp. 2706-2714, 2000.
34. J. A. Karlowsky, G. G. Zhanel, G. W. Hammond et al., "Multidrug-resistantNorth American pulsotype 2 Clostridiumdifficile was the predominant toxigenic hospital-acquired strain in the province of Manitoba, Canada, in 2006-2007, " Journal of Medical Microbiology, vol. 61, no. 5, pp. 693-700, 2012.
35. W. N. Fawley, C. W. Knetsch, D. R. MacCannell et al., "Development and validation of an internationally-standardized, highresolution capillary gel-based electrophoresis PCR-ribotyping protocol for Clostridium difficile, " PLoS ONE, vol. 10, no. 2, Article ID e0118150, 2015.
36. P. Spigaglia and P. Mastrantonio, "Molecular analysis of the pathogenicity locus and polymorphism in the putative negative regulator of toxin production (TcdC) among Clostridium difficile clinical isolates, " Journal of ClinicalMicrobiology, vol. 40, no. 9, pp. 3470-3475, 2002.
37. I. Poilane, P. Cruaud, J. C. Torlotin, and A. Collignon, "Comparison of the E test to the reference agar dilution method for antibiotic susceptibility testing of Clostridium difficile, " Clinical Microbiology and Infection, vol. 6, no. 3, pp. 155-156, 2000.
38. CLSI, Performance Standards for Antimicrobial Susceptibility Testing, 23rd Informational Supplement, CLSI, Wayne, Pa, USA, 2013.
39. EUCAST, Breakpoint Tables for Interpretation ofMICs and Zone Diameters, Version 4. 0, European Committee on Antimicrobial Susceptibility Testing, London, UK, 2014.
40. H. Martin, B. Willey, D. E. Low et al., "Characterization of Clostridium difficile strains isolated from patients in Ontario, Canada, from 2004 to 2006, " Journal of Clinical Microbiology, vol. 46, no. 9, pp. 2999-3004, 2008.
41. H. Martin, L. P. Abbott, D. E. Low, B. Willey, M. Mulvey, and J. S. Weese, "Genotypic investigation of Clostridium difficile in Prince Edward Island, " Canadian Journal of Infectious Diseases and Medical Microbiology, vol. 19, no. 6, pp. 409-412, 2008.
42. Y. Zhou, C.-A. D. Burnham, T. Hink et al., "Phenotypic and genotypic analysis of clostridium difficile isolates: A singlecenter study, " Journal of ClinicalMicrobiology, vol. 52, no. 12, pp. 4260-4266, 2014.
43. M. R. Mulvey, D. A. Boyd, D. Gravel et al., "Hypervirulent Clostridium difficile strains in hospitalized patients, Canada, " Emerging Infectious Diseases, vol. 16, no. 4, pp. 678-681, 2010.
44. R. A. Stabler, D. N. Gerding, J. G. Songer et al., "Comparative phylogenomics of Clostridium difficile reveals clade specificity and microevolution of hypervirulent strains, " Journal of Bacteriology, vol. 188, no. 20, pp. 7297-7305, 2006.
45. M. He, M. Sebaihia, T. D. Lawley et al., "Evolutionary dynamics of Clostridiumdifficile over short and long time scales, " Proceedings of the National Academy of Sciences of the United States of America, vol. 107, no. 16, pp. 7527-7532, 2010.
46. A. Goorhuis, D. Bakker, J. Corver et al., "Emergence of Clostridium difficile infection due to a new hypervirulent strain, polymerase chain reaction ribotype 078, " Clinical InfectiousDiseases, vol. 47, no. 9, pp. 1162-1170, 2008.
47. S. K. Lim, R. L. Stuart, K. E. MacKin et al., "Emergence of a ribotype 244 strain of Clostridiumdifficile associatedwith severe disease and related to the epidemic ribotype 027 strain, " Clinical Infectious Diseases, vol. 58, no. 12, pp. 1723-1730, 2014.
48. M. N. de Almeida, H. Heffernan, A. Dervan et al., "Severe Clostridium difficile infection in New Zealand associated with an emerging strain, PCR-ribotype 244, " New Zealand Medical Journal, vol. 126, no. 1380, pp. 9-14, 2013.
49. C. Quesada-Gómez, D. López-Ureña, L. Acuña-Amador et al., "Emergence of an outbreak-associated Clostridiumdifficile variant with increased virulence, " Journal of Clinical Microbiology, vol. 53, no. 4, pp. 1216-1226, 2015.
50. R. Baldan, A. Trovato, V. Bianchini et al., "Clostridium difficile PCR ribotype 018, a successful epidemic genotype, " Journal of Clinical Microbiology, vol. 53, no. 8, pp. 2575-2580, 2015.
51. F. C. Lessa, Y. Mu, W. M. Bamberg et al., "Burden of Clostridium difficile infection in the United States, " New England Journal of Medicine, vol. 372, no. 9, pp. 825-834, 2015.
52. D. W. Eyre, M. L. Cule, D. J. Wilson et al., "Diverse sources of C. difficile infection identified on whole-genome sequencing, " The New England Journal ofMedicine, vol. 369, no. 13, pp. 1195-1205, 2013.
53. J. R. Argamany, S. L. Aitken, G. C. Lee, N. K. Boyd, and K. R. Reveles, "Regional and seasonal variation in Clostridiumdifficile infections among hospitalized patients in the United States, 2001-2010, " American Journal of Infection Control, vol. 43, no. 5, pp. 435-440, 2015.